INSTRUMENTARIUM/BAXTER/BECTON DICKINSON CONSORTIUM ORCHESTRATES BOC's $1.1 BIL. OHMEDA DIVESTITURE; BD-INSTRUMENTARIUM JOINT VENTURE WILL RUN NOI BUSINESS
This article was originally published in The Gray Sheet
Instrumentarium is acquiring two of Ohmeda's medical products divisions through a consortium organized with Baxter International and Becton Dickinson. The three definitive agreements, which were announced by the participants on Jan. 29, have an aggregate value. of $1.1 bil.
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.